115 – Role of the receptor RAnK and its ligand RAnKL in the development of nAFLD – F. Phan, M. Hu, I. Hainault, V. Ratziu, O. Bourron, F. Foufelle, France

116 – Osteoprotegerin promotes hepatic steatosis through ERK-PPARγ-CD36 pathway – Y. Lin, L. Li, G. Yang, China

117 – nREP bridges tgF-beta signalling and lipid metabolism in the epigenetic programming of nAFLD – D.F. De Jesus, K. Orime, E. Dirice, D. Kaminska, C.-H. Wang, J. Hu, V. Mannisto, A.M. Silva, Y.-H. Tseng, J. Pihlajamaki, R.N. Kulkarni, USA, Portugal, Finland

118 – Role of PKD1 in the control of liver endoplasmic reticulum stress responses during non-alcoholic fatty liver disease progression – P. Rada, A. Mosquera, C. García-Monzón, T. Iglesias, Á.M. Valverde, Spain

119 – Therapeutic effect of a novel long-acting gLP-1/giP/glucagon triple agonist (Hm15211) in nAsH and fibrosis animal models – J. Kim, I. Choi, J. Lee, E. Park, Y. Kim, S. Jung, S. Kim, Korea, Republic of

120 – Patients with an impaired fructolysis are characterised by na increased intrahepatic triglyceride contente – N. Simons, F.-G. Debray, N.C. Schaper, M.E. Kooi, E.J. Feskens, C.E. Hollak, L. Lindeboom, J.A. Bons, D.J. Lefeber, C.G. Schalkwijk, C.D. Stehouwer, D. Cassiman, M.C. Brouwers, Netherlands, Belgium